{"id":70674,"date":"2026-05-12T09:08:38","date_gmt":"2026-05-12T09:08:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70674"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"tirzepatide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/tirzepatide\/","title":{"rendered":"Tirzepatide"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Tirzepatide?<\/h3>\n

Tirzepatide<\/strong> is a 39-amino-acid dual GLP-1 and GIP receptor co-agonist peptide and the active research molecule behind Mounjaro and Zepbound. It produces the largest body-weight and glycaemic effect of any single peptide in current published research, with the dual-receptor profile delivering a meaningfully greater response than single GLP-1 agonists in head-to-head trials such as SURPASS-2. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly dosing. Supplied in 5\u00a0mg to 120\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u0395\u03c1\u03b5\u03c5\u03bd\u03b7\u03c4\u03b9\u03ba\u03ac \u03bb\u03c5\u03bf\u03c6\u03b9\u03bb\u03b9\u03c9\u03bc\u03ad\u03bd\u03b1 \u03c0\u03b5\u03c0\u03c4\u03af\u03b4\u03b9\u03b1 \u00b7 HPLC \u03ba\u03b1\u03b8\u03b1\u03c1\u03cc\u03c4\u03b7\u03c4\u03b1 \u226599% (COA \u03ba\u03b1\u03c4\u03cc\u03c0\u03b9\u03bd \u03b1\u03b9\u03c4\u03ae\u03bc\u03b1\u03c4\u03bf\u03c2) \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03ae \u03c3\u03b5 \u03b8\u03b5\u03c1\u03bc\u03bf\u03ba\u03c1\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c0\u03b5\u03c0\u03c4\u03b9\u03b4\u03af\u03c9\u03bd \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b1 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a><\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u03a0\u03c1\u03bf\u03b4\u03b9\u03b1\u03b3\u03c1\u03b1\u03c6\u03ae<\/th>\n\u039b\u03b5\u03c0\u03c4\u03bf\u03bc\u03ad\u03c1\u03b5\u03b9\u03b1<\/th>\n<\/tr>\n<\/thead>\n
\u0391\u03c1\u03b9\u03b8\u03bc\u03cc\u03c2 CAS<\/strong><\/td>\n2023788-19-2<\/td>\n<\/tr>\n
\u039c\u03bf\u03c1\u03b9\u03b1\u03ba\u03cc\u03c2 \u03a4\u03cd\u03c0\u03bf\u03c2<\/strong><\/td>\nC225<\/sub>H348<\/sub>N48<\/sub>O68<\/sub><\/td>\n<\/tr>\n
\u039c\u03bf\u03c1\u03b9\u03b1\u03ba\u03cc \u0392\u03ac\u03c1\u03bf\u03c2<\/strong><\/td>\n4813.45 Da<\/td>\n<\/tr>\n
\u0391\u03ba\u03bf\u03bb\u03bf\u03c5\u03b8\u03af\u03b1<\/strong><\/td>\nY-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS (39 aa, GIP-based backbone with Aib2<\/sup>, Aib13<\/sup>, and Lys20<\/sup>-C20 fatty diacid acylation via \u03b3Glu-\u03b3Glu spacer)<\/td>\n<\/tr>\n
\u039c\u03bf\u03c1\u03c6\u03ae<\/strong><\/td>\nLyophilized powder (white to off-white)<\/td>\n<\/tr>\n
\u039a\u03b1\u03b8\u03b1\u03c1\u03cc\u03c4\u03b7\u03c4\u03b1<\/strong><\/td>\n\u226599% (HPLC \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03bf, COA \u03ba\u03b1\u03c4\u03cc\u03c0\u03b9\u03bd \u03b1\u03b9\u03c4\u03ae\u03bc\u03b1\u03c4\u03bf\u03c2)<\/td>\n<\/tr>\n
\u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7<\/strong><\/td>\n\u039b\u03c5\u03bf\u03c6\u03b9\u03bb\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf: 2\u20138 \u00b0C (\u03c8\u03c5\u03b3\u03b5\u03af\u03bf) \u03b3\u03b9\u03b1 \u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03b9\u03ba\u03cc \u03b1\u03c0\u03cc\u03b8\u03b5\u03bc\u03b1\u00b7 \u221220 \u00b0C \u03b3\u03b9\u03b1 \u03bc\u03b1\u03ba\u03c1\u03bf\u03c0\u03c1\u03cc\u03b8\u03b5\u03c3\u03bc\u03b7 \u03b1\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7 \u03b1\u03bd\u03bf\u03b9\u03c7\u03c4\u03ce\u03bd \u03c6\u03b9\u03b1\u03bb\u03ce\u03bd. \u0391\u03bd\u03b1\u03c3\u03c5\u03bd\u03c4\u03b5\u03b8\u03b5\u03b9\u03bc\u03ad\u03bd\u03bf: 2\u20138 \u00b0C, \u03c7\u03c1\u03ae\u03c3\u03b7 \u03b5\u03bd\u03c4\u03cc\u03c2 ~30 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd. \u03a0\u03c1\u03bf\u03c3\u03c4\u03b1\u03c3\u03af\u03b1 \u03b1\u03c0\u03cc \u03c4\u03bf \u03c6\u03c9\u03c2. \u039c\u03b7\u03bd \u03ba\u03b1\u03c4\u03b1\u03c8\u03cd\u03c7\u03b5\u03c4\u03b5-\u03b1\u03c0\u03bf\u03c8\u03cd\u03c7\u03b5\u03c4\u03b5 \u03c4\u03bf \u03b1\u03bd\u03b1\u03c3\u03c5\u03bd\u03c4\u03b5\u03b8\u03b5\u03b9\u03bc\u03ad\u03bd\u03bf \u03b4\u03b9\u03ac\u03bb\u03c5\u03bc\u03b1.<\/td>\n<\/tr>\n
\u0394\u03b9\u03b1\u03bb\u03c5\u03c4\u03cc\u03c4\u03b7\u03c4\u03b1<\/strong><\/td>\n\u0392\u03b1\u03ba\u03c4\u03b7\u03c1\u03b9\u03bf\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03cc \u03bd\u03b5\u03c1\u03cc (\u03c0\u03c1\u03bf\u03c4\u03b5\u03af\u03bd\u03b5\u03c4\u03b1\u03b9) \u03ae \u03c3\u03c4\u03b5\u03b9\u03c1\u03c9\u03bc\u03ad\u03bd\u03bf \u03bd\u03b5\u03c1\u03cc \u03b3\u03b9\u03b1 \u03bc\u03b9\u03ba\u03c1\u03cc\u03c4\u03b5\u03c1\u03b1 \u03c7\u03c1\u03bf\u03bd\u03b9\u03ba\u03ac \u03b4\u03b9\u03b1\u03c3\u03c4\u03ae\u03bc\u03b1\u03c4\u03b1 \u03c7\u03c1\u03ae\u03c3\u03b7\u03c2<\/td>\n<\/tr>\n
\u0395\u03c1\u03b5\u03c5\u03bd\u03b7\u03c4\u03b9\u03ba\u03ae \u03a7\u03c1\u03ae\u03c3\u03b7<\/strong><\/td>\n\u039c\u03cc\u03bd\u03bf \u03b3\u03b9\u03b1 \u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03ad\u03c1\u03b5\u03c5\u03bd\u03b1. \u0394\u03b5\u03bd \u03c0\u03c1\u03bf\u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b3\u03b9\u03b1 \u03b4\u03b9\u03b1\u03b3\u03bd\u03c9\u03c3\u03c4\u03b9\u03ba\u03ae \u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u03c7\u03c1\u03ae\u03c3\u03b7 \u03c3\u03b5 \u03b1\u03bd\u03b8\u03c1\u03ce\u03c0\u03bf\u03c5\u03c2 \u03ae \u03b6\u03ce\u03b1.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is Tirzepatide?<\/h2>\n

Tirzepatide<\/strong> is a 39-amino-acid dual incretin receptor co-agonist that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors with comparable potency. Developed by Eli Lilly and disclosed in 2018, it was the first dual-incretin agonist to reach regulatory approval (Mounjaro for type 2 diabetes in 2022, Zepbound for chronic weight management in 2023). Tirzepatide is built on the GIP peptide backbone \u2014 not the GLP-1 backbone used by semaglutide \u2014 with two \u03b1-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 that resist DPP-4 cleavage and a C20 fatty diacid attached at lysine 20 via two \u03b3-glutamic acid spacers. The C20 acyl chain is one carbon longer than semaglutide’s C18, producing tighter albumin binding and a slightly different pharmacokinetic profile.<\/p>\n

Tirzepatide’s well-characterised structure has empirical formula C225<\/sub>H348<\/sub>N48<\/sub>O68<\/sub> with average molecular weight 4813.45 Da. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly subcutaneous dosing in published research. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Pharmaceutical tirzepatide (Mounjaro, Zepbound) is FDA-approved for human therapeutic use under Eli Lilly’s manufacturing controls; the research-grade tirzepatide sold here is supplied \u03bc\u03cc\u03bd\u03bf \u03b3\u03b9\u03b1 \u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03ad\u03c1\u03b5\u03c5\u03bd\u03b1<\/strong> and is not FDA-approved for human or veterinary administration. For broader incretin research, see our Semaglutide<\/a> \u03ba\u03b1\u03b9 Retatrutide<\/a> product pages.<\/p>\n

Mechanism of Action \u2014 Dual GLP-1 \/ GIP Receptor Co-Agonism<\/h2>\n

What differentiates tirzepatide from earlier single-incretin peptides is its balanced co-activation of two distinct receptors<\/strong>, each contributing complementary metabolic effects observed in published research:<\/p>\n